CKW Financial Group’s Sarepta Therapeutics SRPT Stock Holding History

CKW Financial Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-300	Closed	-$6K	–	179
2025 Q4	$6K	Buy	+300	New	+$6.32K	﹤0.01%	135

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CKW Financial Group's SRPT Position: Q1 2026 in Review

CKW Financial Group sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 300 shares — an estimated $6K sold.

CKW Financial Group first reported a position in SRPT in Q4 2025 and held it in 1 quarter. The position peaked at $6K in Q4 2025. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

CKW Financial Group reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
CKW Financial Group sold 300 Sarepta Therapeutics shares in Q1 2026, an estimated $6K.
CKW Financial Group first reported a position in Sarepta Therapeutics in Q4 2025 and held it in 1 quarter.
CKW Financial Group's Sarepta Therapeutics position peaked at $6K in Q4 2025.
339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on CKW Financial Group's 13F filing for Q1 2026, filed 7 May 2026.